Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs

To read the full story, subscribe or sign in.

Two biotech and three med-tech companies are slated for Kosdaq debuts this month, signaling a potential rebound for Korea financings in 2026. Kanaph Therapeutics Inc. will open with a ₩40 billion (US$26.99 million) raise and Imbiologics Corp. will debut with ₩52 billion. Additionally, Mezoo Co. Ltd., Cosmo Robotics Co. Ltd. and Recensmedical Inc. will launch IPOs.

BioWorld Financings Medical technology Wearable Aging Cancer Dermatologic Immune Antibody Antibody-drug conjugate Bispecific antibody Small molecule IPO Asia-Pacific